Gail E. Sonenshein

Gail E. Sonenshein

Auto-generated profile, based on publicly available information

Gail E. Sonenshein

Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2008 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
CMChengyin Min
Chengyin Min
SESean F. Eddy
Sean F. Eddy
DSDavid Sherr
David Sherr
GSGail E. Sonenshein
Gail E. Sonenshein

18 March 2007 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
XWXiaobo Wang
Xiaobo Wang
KBKarine Belguise
Karine Belguise
NKNathalie Kersual
Nathalie Kersual
KKKathrin H. Kirsch
Kathrin H. Kirsch
NMNora D. Mineva
Nora D. Mineva
GSGail E. Sonenshein
Gail E. Sonenshein

30 July 2001 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
KKKathryn T. Kavanagh
Kathryn T. Kavanagh
LHLaurie J. Hafer
Laurie J. Hafer
DKDong W. Kim
Dong W. Kim
KMKoren K. Mann
Koren K. Mann
DSDavid Sherr
David Sherr
GSGail E. Sonenshein
Gail E. Sonenshein

1 October 2004 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
SGShangqin Guo
Shangqin Guo
GSGail E. Sonenshein
Gail E. Sonenshein
The expression status of the estrogen receptor alpha (ERα) and that of the epidermal growth factor receptor Her-2/neu frequently correlate inversely in breast cancers. While ERα-dependent cancers respond to antiestrogen therapy, Her-2/neu-overexpressing cancers typically display resistance to antiestrogens and poor prognosis. In this report we have explored the mechanism linking the loss of expression of ERα in breast cancer cells with overexpression of Her-2/neu, which signals constitutively via a phosphatidylinositol 3-kinase (PI3K)/Akt kinase pathway. We identify for the first time the Forkhead box protein FOXO3a (formerly termed FKHRL-1), which is inactivated by Akt, as a key regulator of ERα gene transcription. In breast cancer cell lines, expression of ERα was correlated with active FOXO3a levels. Ectopic FOXO3a expression induced ERα protein levels and promoter activity, while a dominant negative FOXO3a decreased ERα levels. By using transient transfection, mobility shift assays, and site-directed mutagenesis, two major functional Forkhead binding sites were identified in the human ERα promoter B. A chromatin immunoprecipitation assay confirmed FOXO3a binding at these two sites. Ectopic FOXO3a induced estrogen response element-driven reporter activity and expression of ERα target genes. The constitutively activated myristylated Akt reduced ERα expression, whereas agents that negatively affect the PI3K/Akt pathway, i.e., wortmannin, celecoxib, and the green tea polyphenol epigallocatechin-3 gallate, induced ERα. Thus, FOXO3a represents an important intracellular mediator of ERα expression, suggesting possible therapeutic intervention strategies for Her-2/neu-overexpressing refractory breast tumors.

1 August 2003 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RRRaphaëlle Romieu-Mourez
Raphaëlle Romieu-Mourez
DKDong W. Kim
Dong W. Kim
SSSang Min Shin
Sang Min Shin
EDElizabeth G. Demicco
Elizabeth G. Demicco
ELEsther Landesman-Bollag
Esther Landesman-Bollag
GSGail E. Sonenshein
Gail E. Sonenshein
Amplification, overexpression, or rearrangement of the c-rel gene, encoding the c-Rel NF-κB subunit, has been reported in solid and hematopoietic malignancies. For example, many primary human breast cancer tissue samples express high levels of nuclear c-Rel. While the Rev-T oncogene v-rel causes tumors in birds, the ability of c-Rel to transform in vivo has not been demonstrated. To directly test the role of c-Rel in breast tumorigenesis, mice were generated in which overexpression of mouse c-rel cDNA was driven by the hormone-responsive mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter, and four founder lines identified. In the first cycle of pregnancy, the expression of transgenic c-rel mRNA was observed, and levels of c-Rel protein were increased in the mammary gland. Importantly, 31.6% of mice developed one or more mammary tumors at an average age of 19.9 months. Mammary tumors were of diverse histology and expressed increased levels of nuclear NF-κB. Analysis of the composition of NF-κB complexes in the tumors revealed aberrant nuclear expression of multiple subunits, including c-Rel, p50, p52, RelA, RelB, and the Bcl-3 protein, as observed previously in human primary breast cancers. Expression of the cancer-related NF-κB target genes cyclin D1, c-myc, and bcl-xl was significantly increased in grossly normal transgenic mammary glands starting the first cycle of pregnancy and increased further in mammary carcinomas compared to mammary glands from wild-type mice or virgin transgenic mice. In transient transfection analysis in untransformed breast epithelial cells, c-Rel-p52 or -p50 heterodimers either potently or modestly induced cyclin D1 promoter activity, respectively. Lastly, stable overexpression of c-Rel resulted in increased cyclin D1 and NF-κB p52 and p50 subunit protein levels. These results indicate for the first time that dysregulated expression of c-Rel, as observed in breast cancers, is capable of contributing to mammary tumorigenesis.

1 May 2000 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
DKDong W. Kim
Dong W. Kim
MSMika A. Sovak
Mika A. Sovak
GZGregory Zanieski
Gregory Zanieski
GNGenevieve Nonet
Genevieve Nonet
RRRaphaëlle Romieu-Mourez
Raphaëlle Romieu-Mourez
GSGail E. Sonenshein
Gail E. Sonenshein
NF-κB/Rel is a family of transcription factors which are expressed in all cells; however, in most non-B cells, they are sequestered in the cytoplasm in inactive complexes with specific inhibitory proteins, termed IκBs. We have recently shown that NF-κB/Rel factors are aberrantly activated in human breast cancer and rodent mammary tumors, and function to promote tumor cell survival and proliferation. Here, we have examined the time-course of induction of NF-κB/Rel factors upon carcinogen treatment of female Sprague–Dawley (S–D) rats in vivo and in human mammary epithelial cells (HMECs) in culture. We observed that NF-κB/Rel activation is an early event, occurring prior to malignant transformation. In S–D rats, increased NF-κB/Rel binding was detected in nuclear extracts of mammary glands from 40% of animals 3 weeks post-treatment with 15 mg/kg 7,12-dimethylbenz[a]anthracene (DMBA); this is prior to formation of tumors which normally begin to be detected after 7–9 weeks. In non-tumorigenic MCF-10F cells, in vitro malignant transformation upon treatment with either DMBA or benzo[a]pyrene (B[a]P) resulted in a 4- to 12-fold increase in activity of classical NF-κB (p65/p50). NF-κB induction was corrrelated with a decrease in the stability of the NF-κB-specific inhibitory protein IκB-α. Ectopic expression of the transactivating p65 subunit of NF-κB in MCF-10F cells induced the c-myc oncogene promoter, which is driven by two NF-κB elements, and endogenous c-Myc levels. Furthermore, reduction mammoplasty-derived HMECs, immortalized following B[a]P exposure, showed dysregulated induction of classical NF-κB prior to malignant transformation. Together these findings suggest that activation of NF-κB plays an early, critical role in the carcinogen-driven transformation of mammary glands.